TLDR Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
The document presents a case study of a 14-year-old male patient with severe and refractory alopecia areata (AA), an autoimmune skin disorder causing hair loss, treated with tofacitinib, a Janus kinase (JAK) inhibitor. Previous treatments had yielded suboptimal results. Tofacitinib therapy was initiated at a dose of 5 mg twice daily, leading to complete hair regrowth within 2 months. The dose was then tapered to 5 mg once daily and supplemented with topical therapies. After 5 months, the patient's condition improved significantly, allowing for the discontinuation of tofacitinib. The patient maintained hair growth using topical therapies for a 10-month observation period. No serious adverse events associated with tofacitinib use were observed. The case highlights the potential of tofacitinib as an effective and well-tolerated treatment for AA in adolescents, particularly in the Indian population, and emphasizes the need for further research.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
1 citations,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
2 citations,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
4 citations,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
24 citations,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
5 citations,
June 2015 in “Veterinary dermatology” A dog with complete hair loss regrew most hair after treatment, with no relapse after stopping treatment.
39 citations,
April 2003 in “Australasian journal of dermatology” PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.
